# EDGAR Filing Document

**Accession Number:** 0001581178
**File Stem:** 0001193125-25-223295
**Filing Date:** 2025-9
**Character Count:** 7337
**Document Hash:** 6c5d22be70b9928b5b2d526aa4646227
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-223295.hdr.sgml**: 20250929

**ACCESSION NUMBER**: 0001193125-25-223295

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250929

**FILED AS OF DATE**: 20250929

**DATE AS OF CHANGE**: 20250929

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EUPRAXIA PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001581178
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41923
- **FILM NUMBER:** 251356596

**BUSINESS ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4
- **BUSINESS PHONE:** 250-590-3968

**MAIL ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of September 2025** 

**Commission File Number: 001-41923** 

## Eupraxia Pharmaceuticals Inc.
**(Translation of registrant's name into English)** 

**201-2067 Cadboro Bay Road** 

**Victoria, British Columbia, Canada V8R 5G4** 

**Telephone : (250) 590-3968** 

**(Address of principal executive office)** 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

------

**DOCUMENTS INCLUDED AS PART OF THIS REPORT** 

---

| | |
|:---|:---|
| **Exhibit** |  |
| 99.1 | [Material Change Report, dated September 25, 2025](d946448dex991.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **Eupraxia Pharmaceuticals Inc.** |
|  | (Registrant) |
| Date: September 29, 2025 | /s/ Alex Rothwell |
|  | Alex Rothwell |
|  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**FORM 51-102F3** 

***MATERIAL CHANGE REPORT***

---

| | |
|:---|:---|
| **Item 1:** | **Name and Address of Company**  |

---

Eupraxia Pharmaceuticals Inc. (the "**Company**")

201-2067 Cadboro Bay Rd.

Victoria, British Columbia

Canada, V8R 5G4

---

| | |
|:---|:---|
| **Item 2:** | **Date of Material Change**  |

---

September 24, 2025

---

| | |
|:---|:---|
| **Item 3:** | **News Release**  |

---

A news release announcing the material change was issued on September 24, 2025 through Globe Newswire and a copy was subsequently filed on SEDAR+.

---

| | |
|:---|:---|
| **Item 4:** | **Summary of Material Change**  |

---

On September 24, 2025, the Company announced that it closed its previously announced public offering (the "**Offering**") of 14,636,363 common shares of the Company (the "**Common Shares**"), which includes the issuance of 1,909,090 Common Shares upon full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$5.50 per Common Share for gross proceeds of approximately US$80.5 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering.

---

| | |
|:---|:---|
| **Item 5.1:** | **Full Description of Material Change**  |

---

On September 24, 2025, the Company announced that it closed the Offering of 14,636,363 Common Shares, which includes the issuance of 1,909,090 Common Shares upon full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$5.50 per Common Share for gross proceeds of approximately US$80.5 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering.

Cantor Fitzgerald & Co. and LifeSci Capital LLC acted as joint book-running managers for the Offering. Bloom Burton Securities Inc. also acted as co-manager for the Offering.

The Company intends to use the net proceeds from the Offering primarily for the continued advancement of its product pipeline, including the completion of ongoing preclinical studies and clinical trials, regulatory submissions, and associated commercial preparation and manufacturing scale-up activities. A portion of the proceeds will also be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.

------

The Offering was made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commission (the "**SEC**") on February 7, 2024, and the Company's existing Canadian short form base shelf prospectus, (the "**Base Prospectus**") dated February 5, 2024. A preliminary prospectus supplement and a final prospectus supplement (the "**Supplement**") relating to and describing the terms of the Offering were filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the Offering.

The Supplement and accompanying Base Prospectus can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, from LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at compliance@lifescicapital.com, or from Bloom Burton Securities Inc. at ecm@bloomburton.com.

This material change report shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.

---

| | |
|:---|:---|
| **Item 5.2:** | **Disclosure of Restructuring Transactions**  |

---

Not applicable.

---

| | |
|:---|:---|
| **Item 6:** | **Reliance on subsection 7.1(2) of National Instrument 51-102**  |

---

Not applicable.

---

| | |
|:---|:---|
| **Item 7:** | **Omitted Information**  |

---

Not applicable.

---

| | |
|:---|:---|
| **Item 8:** | **Executive Officer**  |

---

For further information, please contact Alex Rothwell, Chief Financial Officer of the Company at 250-590-3968.

---

| | |
|:---|:---|
| **Item 9:** | **Date of Report**  |

---

September 25, 2025